Accretion Pharmaceuticals Limited (NSE:ACCPL)
India · Delayed Price · Currency is INR 169.90
+6.90 (4.23%)
At close: Jul 31, 2026
Accretion Pharmaceuticals Revenue
In the fiscal year ending March 31, 2026, Accretion Pharmaceuticals had annual revenue of 898.18M INR with 56.54% growth. Accretion Pharmaceuticals had revenue of 459.71M in the half year ending March 31, 2026.
Revenue
898.18M
Revenue Growth
+56.54%
P/S Ratio
2.10
Revenue / Employee
n/a
Employees
125
Market Cap
1.89B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 898.18M | 324.41M | 56.54% |
| Mar 31, 2025 | 573.76M | 440.24M | 329.70% |
| Mar 31, 2024 | 133.53M | -161.79M | -54.79% |
| Mar 31, 2023 | 295.32M | 69.47M | 30.76% |
| Mar 31, 2022 | 225.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bal Pharma | 3.12B |
| Parnax Lab | 2.49B |
| Ambalal Sarabhai Enterprises | 2.03B |
| Sat Kartar Life | 2.01B |
| Gennex Laboratories | 1.73B |
| Oxygenta Pharmaceutical | 1.35B |
| Kerala Ayurveda | 1.31B |
| Coral Laboratories | 859.00M |